12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Other News

Teva endocrine/metabolic news

Teva filed a motion to intervene in the Center for Reproductive Rights' suit against FDA that is seeking unrestricted OTC access to all levonorgestrel-based emergency contraceptives, including Teva's Plan B One-Step and...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >